SCHEMBL3392138

SCHEMBL3392138

Brc1ccccc1C(Br)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.52
TDO2 P48775 1/20 0.52
OPRL1 P41146 3/20 0.39
OPRM1 P35372 2/20 0.39
OPRD1 P41143 2/20 0.39
OPRK1 P41145 2/20 0.39
CES2 O00748 1/20 0.38
CES1 P23141 1/20 0.38
TRPA1 O75762 1/20 0.38
ALDH1A1 P00352 5/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
MAPK1 P28482 1/20 0.36
DPP4 P27487 2/20 0.35
F2 P00734 1/20 0.35
TSHR P16473 1/20 0.35
HTR2A P28223 1/20 0.34
HTT P42858 1/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21831232 0.83 IDO1 (0.38) IDO1TDO2ALDH1A1CYP1A2CYP2C9
SCHEMBL14603365 0.78 IDO1 (0.53) IDO1TDO2OPRL1OPRM1OPRD1
SCHEMBL67123 0.76 CES2 (0.50) CES2CES1TRPA1MAPK1DPP4
SCHEMBL7520144 0.74 IDO1 (0.52) IDO1TDO2OPRL1OPRM1OPRD1
SCHEMBL7522383 0.74 IDO1 (0.50) IDO1TDO2OPRL1OPRM1OPRD1
SCHEMBL11089004 0.74 CES2 (0.37) IDO1TDO2CES2CES1TRPA1
SCHEMBL1641150 0.74 ACP3 (0.48) OPRL1OPRM1OPRD1OPRK1CES2
SCHEMBL29975957 0.74 IDO1 (0.52) IDO1TDO2OPRL1OPRM1OPRD1
SCHEMBL477560 0.74 IDO1 (0.50) IDO1TDO2OPRL1OPRM1OPRD1
SCHEMBL8319597 0.74 IDO1 (0.50) IDO1TDO2OPRL1OPRM1OPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024230246-A1 POLYPEPTIDE RADIONUCLIDE COMPLEX TARGETING FIBROBLAST ACTIVATION PROTEIN AND USE THEREOF 成都纽瑞特医疗科技股份有限公司 2024-11-14 WO claimed
CN-104716352-A Use of crosslinking type polybenzimidazole porous separating membrane in liquid flow battery DALIAN CHEMICAL PHYSICS INST 2015-06-17 CN claimed
WO-2024230246-A1 POLYPEPTIDE RADIONUCLIDE COMPLEX TARGETING FIBROBLAST ACTIVATION PROTEIN AND USE THEREOF 成都纽瑞特医疗科技股份有限公司 2024-11-14 WO disclosed
CN-113754597-B Benzhydryl piperazine compound containing linear olefin and preparation method thereof 凯美克(上海)医药科技有限公司 2024-07-16 CN disclosed
CN-113754597-B Benzhydryl piperazine compound containing linear olefin and preparation method thereof 凯美克(上海)医药科技有限公司 2024-07-16 CN disclosed
CN-109803992-B Isocyanate composition and method for producing isocyanate polymer 旭化成株式会社 2022-05-24 CN disclosed
CN-109843963-B Isocyanate composition, method for producing isocyanate polymer, and isocyanate polymer 旭化成株式会社 2022-05-13 CN disclosed
CN-113754597-A Benzhydrylpiperazine compound containing linear chain olefin and preparation method thereof 凯美克(上海)医药科技有限公司 2021-12-07 CN disclosed
CN-113754597-A Benzhydrylpiperazine compound containing linear chain olefin and preparation method thereof 凯美克(上海)医药科技有限公司 2021-12-07 CN disclosed
CN-113754666-A Benzopyrazine compound and synthesis method thereof 凯美克(上海)医药科技有限公司 2021-12-07 CN disclosed
CN-104716352-A Use of crosslinking type polybenzimidazole porous separating membrane in liquid flow battery DALIAN CHEMICAL PHYSICS INST 2015-06-17 CN disclosed
EP-1711617-A1 METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTICS COMPOUNDS GILEAD SCIENCES, INC. (US) 2006-10-18 EP disclosed
WO-2005064008-A9 METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS GILEAD SCIENCES INC (US) 2006-09-28 WO disclosed
EP-1673336-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS Merck Frosst Canada Ltd. (CA) 2006-06-28 EP disclosed
US-20050239054-A1 Method and compositions for identifying anti-HIV therapeutic compounds GILEAD SCIENCES. INC. 2005-10-27 US disclosed
US-20050209197-A1 Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds GILEAD SCIENCES, INC. 2005-09-22 US disclosed
WO-2005064008-A1 METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. (US) 2005-07-14 WO disclosed
WO-2005019161-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK FROSST CANADA LTD. (CA) 2005-03-03 WO disclosed
EP-1509537-A2 CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH GILEAD SCIENCES, INC. (US) 2005-03-02 EP disclosed
WO-2003090690-A2 CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH GILEAD SCIENCES, INC. (US) 2003-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050209197-A1 Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds PPA1, PPME1, PNP IDO1 2602/4885TDO2 4250/4885OPRL1 4463/4885
US-20050239054-A1 Method and compositions for identifying anti-HIV therapeutic compounds CES1, PNP, PGLS IDO1 3997/4885TDO2 4089/4885OPRL1 4133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.